Overview

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Status:
Recruiting
Trial end date:
2023-08-04
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib to participants from Incyte-sponsored studies of parsaclisib.
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation